Find information on thousands of medical conditions and prescription drugs.

Femara

Letrozole (Femara®) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast cancer. more...

Home

Femara

Femring

Filipin

Flagyl

Flarex

Flavoxate

Flecainide

Flexeril

Flomax

Flonase

Flovent

FML

Focalin

Fosamax

Frova

Fuzeon

Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Letrozole blocks this activity by competitive, reversible binding to the heme of its cytochrome p450 unit. The action is specific, and letrozole does not reduce production of mineralo- or corticosteroids. In contrast, Tamoxifen, the major medical therapy prior to the arrival of aromatase inhibitors, does effect its antiestrogenic action by interfering with the estrogen receptor, not the estrogen production.

Letrozole is approved by the FDA for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status. Side effects include signs and symptoms of hypoestrogenism. There is concern that long term use may lead to osteoporosis.

A related agent is anastrozole.

Read more at Wikipedia.org

• [List your site here Free!]



	Femara takes the cancer world by storm—part 2 - The War on Cancer In last month's column I began a discussion of a major clinical trial of the new drug Femara. This showed that although Femara did have a positive impact ... From Townsend Letter for Doctors and Patients, 2/1/04 by Ralph W. Moss

	The war on cancer; Femara takes the cancer world by storm—Part 1 It is being hailed as the biggest break-through in the treatment of breast cancer in years. An anti-estrogen drug called Femara (letrozole) has been ... From Townsend Letter for Doctors and Patients, 1/1/04 by Ralph W. Moss

	Study shows advantage for new breast cancer drug—many questions remain. aromatase inhibitor - letrozole Femara The news was so important that The New England Journal of Medicine announced the study results three weeks earlier than the planned publication date. From Healthfacts, 12/1/03

	Femara Approved as First-Line Breast Cancer Therapy - Brief Article The Food and Drug Administration has approved a new use for the breast cancer drug Femara (letrozole). Femara had been approved to treat women with advanced breast cancer who had not responded to a From FDA Consumer, 5/1/01

	Femara wins breast cancer indication - Food and Drug Administration approval - Brief Article Femara (letrozole tablets), a Novartis drug used in metastatic breast cancer patients who failed tamoxifen or other traditional therapies, received Food ... From Drug Store News, 4/23/01

	Femara gets first-line indication - Novartis AG - Brief Article The FDA approved Femara (letrozole), a breast cancer drug from Novartis, as a first-line treatment for postmenopausal women with hormone receptor positive ... From Drug Store News, 2/19/01 by James Frederick

	FDA advisory committee favors Femara approval for breast cancer - Brief Article The FDA's oncologic drugs advisory committee recommended approval of Femara (letrozole) tablets as first-line hormonal treatment for advanced breast cancer in postmenopausal women. Femara is a produ From Drug Store News, 1/15/01

	Tamoxifen alone discouraged as adjuvant Tx HOLLYWOOD, FLA. -- An aromatase inhibitor, either alone or after tamoxifen therapy, is better than tamoxifen alone for the long-term prevention of breast ... From OB/GYN News, 5/1/05 by Diana Mahoney

Home

Contact

Resources

Exchange Links

ebay